TYRA - מזומני החברה tyra.bio

Flawless laboratory readiness ensures a steady pace of development, as confirmed by the cash runway chart. The current value of 0.70 describes the liquidity level of Tyra Biosciences, Inc. (TYRA). The company relies on the SNAP AI system to create precision medicines, while growth potential is driven by the success of the drug TYRA-300 and its orphan drug status, which is attracting the attention of the market's largest behemoths.
פילוחי נתונים אנליטיים מרוכזים עבור Tyra Biosciences Inc (TYRA)

This metric measures the volume of liquid assets, allowing investors to differentiate speculative volatility from fundamental stability by analyzing interest income and operational flexibility. By examining the cash trajectory on the GURU.Markets platform, one can assess the ability of Tyra Biosciences, Inc. (TYRA) to fund the development of selective FGFR inhibitors, which is critical for scaling its technological advantage in oncology.